EMA Authorised: Idefirix (imlifidase) — Hansa Biopharma AB

View source ↗

Summary

The EMA authorised Idefirix (imlifidase) from Hansa Biopharma AB for desensitization to enable kidney transplantation in highly sensitised patients, under condi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Kidney Transplantation

Drugs mentioned

• Idefirix (imlifidase)

Snippet

Status: Authorised. Therapeutic area: Desensitization, Immunologic;Kidney Transplantation. MAH: Hansa Biopharma AB. Decision date: 25/06/2025. Conditional approval. Orphan medicine